IOA 359
Alternative Names: IOA-359Latest Information Update: 01 Feb 2024
At a glance
- Originator Clavius Pharmaceuticals
- Developer iOnctura
- Class Antineoplastics; Small molecules
- Mechanism of Action TGF-beta superfamily protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 09 Dec 2023 Preclinical trials in Acute myeloid leukaemia in Switzerland (PO), prior to December 2023
- 09 Dec 2023 Preclinical trials in Myelodysplastic syndromes in Switzerland (PO), prior to December 2023
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Myelodysplastic syndromes and Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)